Showing results (661-670 of 726) with videos related to
Sort By:
Pageof 73
Science Signaling|July 20, 2022
A CRISPR screen targeting PI3K effectors identifies RASA3 as a negative regulator of LFA-1-mediated adhesion in T cellsKristoffer H Johansen, Dominic P Golec, Bonnie Huang, et al.The Journal of Allergy and Clinical Immunology|March 5, 2025
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA boosterBrianna T Wachter, Qin Xu, Lihong Shi, et al.Cancer Medicine|March 25, 2018
An open-label, dose-ranging study of Rolontis, a novel long-acting myeloid growth factor, in breast cancerJeffrey L Vacirca, Arlene Chan, Klára Mezei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.Clinical Breast Cancer|August 24, 2017
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast CancerJosé Baselga, Claudio Zamagni, Patricia Gómez, et al.Nature Immunology|April 27, 2023
Dynamic chromatin accessibility licenses STAT5- and STAT6-dependent innate-like function of TH9 cells to promote allergic inflammationAran Son, Francoise Meylan, Julio Gomez-Rodriguez, et al.Immunity|July 8, 2010
Regulation of microRNA expression and abundance during lymphopoiesisStefan Kuchen, Wolfgang Resch, Arito Yamane, et al.The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.European Journal of Cancer (Oxford, England : 1990)|April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trialChris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.The Journal of Experimental Medicine|June 15, 2019
Mg2+ regulation of kinase signaling and immune functionChryssa Kanellopoulou, Alex B George, Evan Masutani, et al.Pageof 73